NewAmsterdam Pharma
NAMS
100 hedge funds and large institutions have $1.28B invested in NewAmsterdam Pharma in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 45 increasing their positions, 17 reducing their positions, and 10 closing their positions.
1,723% more call options, than puts
Call options by funds: $1.09M | Put options by funds: $60K
165% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 17
110% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 10
11% more funds holding
Funds holding: 90 → 100 (+10)
5.62% more ownership
Funds ownership: 80.02% → 85.64% (+5.6%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
7% less capital invested
Capital invested by funds: $1.38B → $1.28B (-$104M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$11.8M |
| 2 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$10.9M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$9.01M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$8.69M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$6.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$19.9M |
| 2 |
AG
Artal Group
Luxembourg
|
-$15.4M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.6M |
| 4 |
SCM
Superstring Capital Management
New York
|
-$1.23M |
| 5 |
GC
GMT Capital
Atlanta,
Georgia
|
-$1.09M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AG
101
Artal Group
Luxembourg
| – | -$15.4M | -800,000 | Closed |
|
|
SCM
102
Superstring Capital Management
New York
| – | -$1.23M | -64,213 | Closed |
|
|
SSA
103
Schonfeld Strategic Advisors
New York
| – | -$950K | -49,433 | Closed |
|
|
JGC
104
J. Goldman & Co
New York
| – | -$706K | -36,776 | Closed |
|
|
VPC
105
Vestal Point Capital
New York
| – | -$480K | -25,000 | Closed |
|
|
ACP
106
Acuta Capital Partners
Redwood City,
California
| – | -$432K | -22,500 | Closed |
|
|
YIH
107
Y-Intercept (HK)
Hong Kong
| – | -$281K | -14,607 | Closed |
|
|
PL
108
Parkwood LLC
Cleveland,
Ohio
| – | -$265K | -13,782 | Closed |
|
109
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$234K | -12,171 | Closed |
|
|
BCV
110
Banque Cantonale Vaudoise
Lausanne,
Switzerland
| – | -$38K | -2,000 | Closed |
|
NAMS Hedge Fund Activity: Q3 2024 in Review
100 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in NewAmsterdam Pharma (NAMS) for Q3 2024, worth a combined $1.28B — down 7.5% from $1.38B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new NAMS positions and 10 closed out — a net gain of 11 holders — while 45 added to existing stakes and 17 trimmed.
The largest buyer was Woodline Partners, adding an estimated $11.8M. The largest seller was Millennium Management, cutting an estimated $19.9M.
- 100 institutional investors held NewAmsterdam Pharma (NAMS) as of Q3 2024, up from 90 in Q2 2024.
- Funds reported $1.28B of NewAmsterdam Pharma stock for Q3 2024, down 7.5% quarter-over-quarter.
- 21 funds opened new NewAmsterdam Pharma positions in Q3 2024 and 10 closed out, a net change of +11 holders.
- The largest NewAmsterdam Pharma buyer in Q3 2024 was Woodline Partners, an estimated $11.8M added.
- The largest NewAmsterdam Pharma seller in Q3 2024 was Millennium Management, an estimated $19.9M sold.
Based on aggregated 13F filings for Q3 2024.